Lung cancer · J Clin Oncol · 2022
The paper’s summary says 52.6% of 15 patients responded. Its own count: 7 of 15 (46.7%).
Share of patients whose tumors shrank or vanished, depending on who is counted
The paper says
In a lung-cancer drug trial, the paper’s summary says 52.6% of the group it singles out responded (their tumors shrank or vanished): 15 patients whose tumors had a lot of c-Met, the protein one drug targets, and a change in a gene called EGFR.
Its own data show
With 15 patients, 7 responders is 46.7% and 8 is 53.3%; 52.6% is impossible. The paper’s results count 7 responders among those 15. 52.6% is 10 of 19, the results’ rate for all 19 patients with a lot of c-Met: the 15 plus 4 not in the EGFR-change group, 3 of whom responded.
A response rate is responders divided by patients counted, so it shifts with who is counted. This is the summary’s only figure for the group the paper says matters most. It reads as more than half; the real figure is just under half. These 15 still respond more often than all patients with the EGFR change: 32.1% (9 of 28).